Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Terminated · Phase 1 · NCT06916143
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $166,463
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 1
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4100511 (drug), Rabeprazole (drug)
- Dates
- Started 2025-04-08; completion 2025-04-08
- Results posted
- Not yet
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
From ClinicalTrials.gov, last updated 2026-09-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $166,463 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- William T. Smith IV, MD Cardiac Electrophysiology · Wilmington, NC
- Alexander N. Prezioso, M.D. Specialist · Lake Hopatcong, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Erg Holding Co LLC DBA St Louis Clinical Trials LLC $149,236
- Alliance for Multispecialty Research Lls $17,228
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.